What you should know:
1. Pfizer is using a combination of encorafenib and cetuximab to treat mCRC.
2. The combination therapy improved overall survival and objective response rates for mCRC when compared to patients taking cetuximab with irinotecan-containing regimens, according to a study published in the New England Journal of Medicine.
3. If the FDA approves the combination therapy, it would become the first targeted regimen for mCRC patients who harbor a BRAF mutation, said Chris Boshoff, MD, PhD, Pfizer’s chief development officer of oncology.
4. BRAF gene mutation occurs in up to 15 percent of patients with mCRC.
More articles on surgery centers:
Robotics might not be worth the ‘tremendous’ investment for ASCs — 2 leaders explain why
12 ASCs adding total joint replacements in 2019
Crystal Clinic Orthopedic Center celebrates northeast Ohio opening
